Glenmark Pharmaceuticals Quarterly Results

Latest Quarter Net Profit
₹264 Cr
QSept 2026
Quarterly Results

Glenmark Pharmaceuticals quarterly results. In Sept 2026, Glenmark Pharmaceuticals (GLENMARK) reported revenue ₹4,160 Cr and net profit ₹264 Cr — revenue -32.9% YoY. Also explore GLENMARK share price history to track price trends across different timeframes.

GLENMARK Quarterly Results — Revenue, Profit & EPS Highlights

Glenmark Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. View GLENMARK 52-week performance for the annual high/low range and current price position.

  • Revenue of ₹4,160 Cr in Sept 2026 (+5.3% vs Mar 2026, -32.9% vs Sept 2025)
  • Net Profit of ₹264 Cr in Sept 2026 (-12.3% vs Mar 2026, -56.7% vs Sept 2025)
  • EBITDA of ₹492 Cr in Sept 2026 (-13.4% vs Mar 2026)
  • Operating Margin of 12.0% in Sept 2026 (+2.0pp vs Mar 2026)
  • Earnings Per Share of ₹9.35 in Sept 2026 (-12.5% vs Mar 2026)

Glenmark Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS

GLENMARK quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Sept 2026 Mar 2026 Jun 2026 Sept 2025 Mar 2025 QoQ YoY
Revenue (₹ Cr) 4,160 3,949 3,998 6,204 3,232 5.3% -32.9%
Net Profit (₹ Cr) 264 301 483 610 4 - -
EBITDA (₹ Cr) 492 568 784 1,132 164 - -
EPS (₹) 9.35 10.68 17.11 21.63 0.16 - -
Operating Margin (%) 12.0% 10.0% 18.0% 16.0% 5.0% - -

GLENMARK Share Price Trend — 1-Year Movement Across Quarterly Results

Glenmark Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Glenmark Pharmaceuticals screener.

Profitability Ratios

Profit Margin 6.3%
EBITDA Margin 11.8%
Operating Margin 12.0%
ROE (Annual) 10.0%

Balance Sheet Highlights

Total Assets ₹19,908 Cr
Total Equity ₹10,512 Cr
Current Assets ₹ Cr
Current Liabilities ₹3,020 Cr

Cash Flow Analysis

Operating Cash Flow ₹3,445 Cr
Investing Cash Flow ₹-1,237 Cr
Financing Cash Flow ₹-2,709 Cr
Net Cash Flow ₹-501 Cr

Current Market Data

Current Price ₹2608.50
Exchange NSE
Last Updated Nov 19, 2026

GLENMARK vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Glenmark Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Sept 2026
₹451,074.97 Cr 1900.0 16,617 1,995 +10.6% - 12.0% 228.9
Divis Laboratories
Sept 2026
₹294,139.19 Cr 11178.0 3,770 1,127 +26.3% - 29.9% 263.1
Torrent Pharmaceuti…
Mar 2026
₹188,719.51 Cr 4611.0 4,111 364 +27.7% +42.2% 8.9% 400.6
Apollo Hospitals
Sept 2026
₹126,832.45 Cr 8738.0 7,673 660 +15.2% - 8.6% 199.4
Laurus Labs
Sept 2026
₹125,946.78 Cr 2306.0 2,219 436 +21.7% - 19.6% 282.3
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data

QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores